Mechanisms of Pulmonary Vasculopathy in Acute and Long-Term COVID-19: A Review.

Fiche publication

Date publication

avril 2024

Journal

International journal of molecular sciences

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GENY Bernard

Tous les auteurs :
Riou M, Coste F, Meyer A, Enache I, Talha S, Charloux A, Reboul C, Geny B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38732160

Résumé

Despite the end of the pandemic, coronavirus disease 2019 (COVID-19) remains a major public health concern. The first waves of the virus led to a better understanding of its pathogenesis, highlighting the fact that there is a specific pulmonary vascular disorder. Indeed, COVID-19 may predispose patients to thrombotic disease in both venous and arterial circulation, and many cases of severe acute pulmonary embolism have been reported. The demonstrated presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within the endothelial cells suggests that direct viral effects, in addition to indirect effects of perivascular inflammation and coagulopathy, may contribute to pulmonary vasculopathy in COVID-19. In this review, we discuss the pathological mechanisms leading to pulmonary vascular damage during acute infection, which appear to be mainly related to thromboembolic events, an impaired coagulation cascade, micro- and macrovascular thrombosis, endotheliitis and hypoxic pulmonary vasoconstriction. As many patients develop post-COVID symptoms, including dyspnea, we also discuss the hypothesis of pulmonary vascular damage and pulmonary hypertension as a sequela of the infection, which may be involved in the pathophysiology of long COVID.